Fueling up: Auspex files to raise $60M to carry SD-809 to success
Just five months after raising about $94.8 million in a well-received initial public offering (IPO), Auspex Pharmaceuticals Inc. has priced a new follow-on offering expected to raise an additional $60.6 million to carry a new pivotal trial of its lead candidate, SD-809 (deutetrabenazine), in the movement disorder tardive dyskinesia and to support the company through at least the second quarter of 2016.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter